Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOCLEAR L A 260.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOCLEAR L A 260.
AQUAPHYLLIN vs THEOCLEAR L.A.-260
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Category C
Category C
Bronchodilator
Bronchodilator